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ORIGINAL ARTICLE
Precocious puberty is usually defined as the ap-
pearance of secondary sexual characteristics before
the age of 8 years in girls and 9 years in boys.1
Gonadotropin-dependent precocious puberty,
also known as central precocious puberty (CPP),
is caused by the premature activation of gonado-
tropin releasing hormone (GnRH) pulse genera-
tor in the hypothalamus.2 It may be caused by
intracranial organic lesions such as hamartoma,
hydrocephalus and infection, or occur without
obvious lesion. Patients with CPP usually have
acceleration of the tempo of puberty and bone age
maturation resulting in early fusion of epiphyseal
growth plates and short adult height.3
Synthetic GnRH analogues (GnRHa) have been
introduced as suppressive therapy for CPP since
1981.4 Continuous administration of GnRH will
downregulate the GnRH receptors of the pituitary
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Background/Purpose: It has been reported that gonadotropin releasing hormone analogue (GnRHa)
therapy can improve the adult height of patients with gonadotropin-dependent precocious puberty. The
purpose of this study was to evaluate the effect of GnRHa on the adult height of girls with gonadotropin-
dependent precocious puberty and the adverse effects of such therapy.
Methods: Between 1989 and 2006, 11 girls with gonadotropin-dependent precocious puberty who had
been treated with GnRHa and reached their adult height were enrolled in the present study. Follow-up
studies of bone age, pelvic sonography and GnRH test were done regularly during the period of treatment.
All patients had bone mineral density examined at least 2 years after completion of GnRHa therapy.
Results: GnRHa therapy was initiated at the age of 8.0 ± 1.5 years. The predicted adult height immedi-
ately before GnRHa therapy was 146.7 ± 4.8 cm (−2.3 ± 0.9 standard deviation [SD]). The duration of
GnRHa therapy was 4.7 ± 1.8 years. The adult height of the patients was 156.3 ± 4.3 cm (−0.6 ± 0.8 SD),
which is similar to their target height of 157.0 ± 4.5 cm (−0.5 ± 0.8 SD). The uterine sizes and go-
nadotropin responses to GnRH stimulation were well suppressed during treatment. Menstruation 
resumed 9.2 ± 5.9 months after the discontinuation of treatment in these patients. Forty-five percent of 
patients had lumbar bone mineral density less than 1 SD below that of normal young Taiwanese adults 
in the Taipei region.
Conclusion: GnRHa therapy can improve the adult height of patients with gonadotropin-dependent 
precocious puberty. However, 45% of patients had decreased bone accretion during therapy. [J Formos Med
Assoc 2007;106(10):826–831]
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gland and desensitize the pituitary response to
GnRH, resulting in suppression of the secretion
of downstream gonadotropins and sex hormones.5
There is some evidence that suppression of the
abnormal progression of puberty in patients with
CPP can prolong the period of growth in these
children and improve their adult height.6,7
There has been concern about the side effects
of long-term GnRHa therapy in children.8 The
recovery of the hypothalamus–pituitary–gonad
axis and resumption of menstruation has been
demonstrated.9,10 However, the effect on bone
mineral density (BMD) is still inconclusive.11,12
Our study aimed to evaluate the efficacy of long-
term GnRHa therapy and its possible adverse 
effects in Taiwanese girls with CPP.
Materials and Methods
Subjects
Between 1989 and 2006 at the pediatric endocrine
clinic of National Taiwan University Hospital, there
were 13 girls with CPP who had been treated with
GnRHa and who reached their adult height. Two
of them who had been treated with GnRHa and
growth hormone because of the coexistence of
growth hormone deficiency were excluded. Thus,
11 girls were enrolled for evaluation in the present
study.
The etiologies of the 11 patients were as fol-
lows: three had hypothalamic hamartoma, one 
had post-traumatic hydrocephalus, and seven were
classified as idiopathic. There was no statistically
significant difference in the auxological data be-
fore treatment between these two groups except
that the patients with central nervous system lesion
had their onset of puberty at a younger age than
those with idiopathic CPP (3.9 ± 1.7 years vs.
6.0±2.4 years). Therefore, their data were grouped
together in the discussion.
The 11 girls started GnRHa therapy at the age
of 8.0 ± 1.5 years. All of the patients had demon-
strated that their gonadotropin levels were 
responsive to GnRH stimulation before treat-
ment, which was considered the criterion for the
confirmation of their gonadotropin dependence.
Their bone age at the start of treatment was
11.5 ± 1.3 years, which was advanced more than
2 standard deviations (SDs) above their chrono-
logical age.
Protocol
Before 1992, two patients had subcutaneous leu-
prolide acetate 40 µg/kg/day once daily as initial
treatment, and depot preparation of subcutaneous
triptorelin or leuporelin 3.75 mg once a month
was prescribed after 1992 when the depot form
of GnRHa became available in Taiwan. Three fac-
tors including (1) bone age > 14 years, (2) growth
velocity < 2 cm/year or (3) the family’s satisfac-
tion with the patient’s height were considered
when deciding on the appropriate time to stop
GnRHa therapy.
Patients’ height (measured with a stadiometer),
weight and signs of puberty were evaluated once
every 3 months. They underwent bone age study
and pelvic sonography once every 6 months.
Bone age was assessed according to Greulich and
Pyle’s criteria.13 Predicted adult height (PAH) was
calculated according to the method of Bayley and
Pinneau.14 GnRH test was done at 3 months, 1
year and then once every 6 months after GnRHa
therapy. The uterine volumes were measured by
the same technician. Uterine size, including its
length, and largest anteroposterior and transverse
diameters, was measured using ultrasonography,
and uterine volume was estimated using the for-
mula for a prolate ellipsoid.15 GnRH stimulation
test was performed with intravenous GnRH 0.1mg,
and serum follicle-stimulating hormone (FSH)
and luteinizing hormone (LH) levels were mea-
sured at baseline, 30, 60, 90 and 120 minutes after
GnRH stimulation. Adult height was measured
when bone age exceeded 16 years and the growth
rate was less than 0.5 cm per year. The adult height
of these patients was measured at the age of 19.8±
2.0 years. We performed dual energy X-ray ab-
sorptiometry (DEXA) (Norland XR26; Norland
Corp., Fort Atkinson, WI, USA) to determine 
vertebral BMD at L2 to L4 in these patients at
least 2 years after completion of GnRHa therapy.
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The data were compared with those of normal
young Taiwanese adults in the Taipei region.
Statistical analysis
All auxological data are expressed as mean ± SD
except the data in the figures. The grouping data
were analyzed statistically using the Mann-
Whitney U test. The paired data were compared
by the Wilcoxon signed-rank test. A p value of less
than 0.05 was considered statistically significant.
Results
Before treatment, serum FSH levels rose from
6.0 ± 2.9 mIU/mL to 15.3 ± 0.8 mIU/mL, and
serum LH levels rose from 4.1 ± 3.4 mIU/mL to
29.7 ± 23.5 mIU/mL after GnRH stimulation.
After GnRHa therapy for 3 months, the peak FSH
and LH levels after GnRH stimulation were 2.0 ±
1.2 and 1.3 ± 1.5 mIU/mL, respectively. As shown
in Figure 1, the hypothalamus–pituitary–ovary
axis was well suppressed during the period of
GnRHa treatment. Pubertal response to GnRH
test was observed within 6 months after the dis-
continuation of GnRHa therapy, and menstrua-
tion resumed 9.2 ± 5.9 months (range, 3 months
to 2 years) after the discontinuation of therapy.
Five patients had vaginal bleeding during the
first month after therapy and eight patients had
their breast regress to Tanner stage I after therapy.
As shown in Figure 2, the uterine volume of the
patients decreased from 9.7 ± 4.0 cm3 to 4.3 ±
2.6 cm3 after GnRHa therapy for 6 months (p <
0.01). Their uterine volume remained stationary
during the period of therapy and it increased to
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Figure 1. Peak follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH) responses to
GnRH stimulation in patients with gonadotropin-
dependent precocious puberty during the course
of GnRHa therapy. *p < 0.05 compared to the
value at the start of therapy; ‡p < 0.05 compared
to the value at the end of therapy. End = time of
discontinuation of GnRHa therapy; End + 0.5 =
6 months after the discontinuation of GnRHa 
therapy. Data are expressed as mean ± SEM.
Figure 2. Evolution of uterine size in patients with
gonadotropin-dependent precocious puberty during
the course of GnRHa therapy. *p < 0.05 compared to
the value at the start of therapy; ‡p < 0.05 compared
to the value at the end of therapy. End = time of 
discontinuation of GnRHa therapy; End + 0.5 =
6 months after the discontinuation of GnRHa 
therapy. Data are expressed as mean ± SEM.
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22.7 ± 7.4 cm3 6 months after the discontinuation
of GnRHa therapy.
The target height of the patients in this study
was 157.0 ± 4.5 cm (−0.5 ± 0.8 SD). They started
GnRHa therapy at the age of 8.0 ± 1.5 years. As
shown in Figure 3, the growth velocity was 7.3 ±
1.5 cm/year immediately before therapy, and 
decreased to 6.1 ± 1.5 cm/year at the first year,
3.9 ± 1.2 cm/year at the second year, and 3.2 ±
1.3 cm/year at the third year. As shown in Figure
4A, the progression of bone age was significantly
decreased from 2.4 ± 1.4 years per year before
therapy to 0.5 ± 0.7 years per year at the first year
of therapy. Patients stopped GnRHa therapy at the
age of 12.7 ± 0.9 years, with a bone age of 13.6 ±
0.6 years. At that time, their height was 149.0 ±
5.0 cm. Bone age increased 1.1 ± 0.4 years at the
first year after the discontinuation of GnRHa ther-
apy. During the course of 4.7 ± 1.8 years of GnRHa
therapy (range, 3.0–8.0 years), their bone age in-
creased 2.0 ± 1.6 years and their height gain was
19.0 ± 10.0 cm during the same period. Therefore,
their adult height of 156.3±4.3 cm (−0.6±0.8 SD)
was significantly higher than their PAH of 146.7±
4.8 cm (−2.3 ± 0.9 SD) at the start of therapy (p <
0.01), as shown in Figure 4B.
Except for local discomfort at injection sites,
there were no other serious adverse effects noted
during the course of treatment. BMD was deter-
mined when the patients were 20.0±1.9 years old,
which was 7.3 ± 2.5 years after the discontinuation
of GnRHa therapy. The BMD of their lumber spine
was 0.99 ± 0.13 g/cm3, which was −0.9 ± 1.0 SD
(range, −2.4 to 0.8 SD) in comparison with the
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Figure 4. Changes in (A) bone age progression and (B) predicted adult height during the course of GnRHa therapy.
*p < 0.05 compared to the value at the start of therapy; ‡p < 0.05 compared to the value at the end of therapy. End = time
of discontinuation of GnRHa therapy; End + 1 = 1 year after the discontinuation of GnRHa therapy. Data are expressed 
as mean ± SEM.
Figure 3. Change in growth velocity during the
course of GnRHa therapy. *p < 0.05 compared 
to the value at the start of therapy; ‡p < 0.05 
compared to the value at the end of therapy.
End = time of discontinuation of GnRHa therapy;
End + 1 = 1 year after the discontinuation of 
GnRHa therapy. Data are expressed as
mean ± SEM.
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data of normal young Taiwanese adults in the
Taipei region. Five of the 11 patients (45%) had
their BMD below −1 SD, which was defined as
osteopenia. No correlation between BMD and
duration of treatment was found.
Discussion
Our study showed that the activated hypothala-
mus–pituitary–ovary axis of patients with CPP
was suppressed after 3 months of GnRHa therapy,
and it remained well suppressed throughout the
course of GnRHa therapy. In addition, the breast
decreased in size and remained in prepubertal
stage in most of the patients. Withdrawal bleed-
ing was also observed during the first month after
the start of GnRHa therapy in patients who had
well-developed uterus. The uterine size of treated
patients regressed rapidly within 6 months after
therapy and remained stationary throughout the
course of GnRHa therapy. All of these data reflect
the fact that the hypothalamus–pituitary–ovary
axis was effectively suppressed by GnRHa therapy.
This study also demonstrated that the inappro-
priate progression of bone age maturation was
slowed down by GnRHa therapy through a dep-
rivation of estrogen effect by the suppression of the
hypothalamus–pituitary–ovary axis in these pa-
tients. It was reported that the continuous growth
of patients under GnRHa therapy can improve
their adult height.16 In this study, the bone age of
the patients matured only 2 years during a course
of 4.7 years of treatment, while they grew 19.0 cm
during the same period of time. Thus, they had a
mean adult height of 156.3 cm (−0.6 SD), which
was close to their target height of 157.0 cm 
(−0.5 SD) and significantly taller than their PAH
of 146.7 cm (−2.3 SD) at the start of GnRHa ther-
apy. These results are consistent with previously
reported data.11,12,16,17
The reversibility of suppression of the hypo-
thalamus–pituitary–ovary axis was also well
demonstrated in our patients. Their serum go-
nadotropin levels showed a pubertal response to
GnRH stimulation and their uterine size enlarged
within 6 months after the discontinuation of
GnRHa therapy. All experienced resumption of
menstrual flow within 2 years after the discon-
tinuation of GnRHa therapy. Such findings are
consistent with a previous report.9
The introduction of long-acting depot prepa-
rations of GnRHa has improved patient compli-
ance due to the advantage of a reduced frequency
of injection, which is one of the important fac-
tors that makes long-term compliance to sup-
pressive therapy possible.5,18,19 Except for local
pain at the injection sites, no other serious ad-
verse effects were detected in our patients during
the period of GnRHa therapy.
Bone mineral accretion is a complex process
and estrogen may play an important role in it.20–22
GnRHa therapy suppresses the hypothalamus–
pituitary–ovary axis, which theoretically may 
decrease the accretion of bone mass, resulting in
osteopenia or osteoporosis. Forty-five percent 
of the patients in this study had osteopenia in
contrast to previous reports where no significant
change in BMD was observed after GnRHa ther-
apy.11,23 On the other hand, Heger et al reported
that the lumbar spine BMD of CPP patients treated
with GnRHa was not significantly different from
that of control subjects, but they noticed that 15%
of their patients had osteopenia.12 Yanovski et al
also reported that 82% of their patients treated
with GnRHa had BMD more than 1 SD below the
population.24 Further studies are indicated to
clarify such a discrepancy. Studies on the preven-
tion of low BMD in CPP patients treated with
GnRHa have rarely been reported. Antoniazzi 
et al found that the BMD in CPP patients treated
with GnRHa and calcium supplementation was
better preserved than the BMD of CPP patients not
given calcium supplementation.23 Further studies
are necessary to confirm this.
In conclusion, GnRHa therapy can effectively
suppress the prematurely activated hypothalamus–
pituitary–ovary axis and improve the adult height
of patients with gonadotropin-dependent preco-
cious puberty. However, reduced BMD is a possible
major side effect that should be seriously consid-
ered during long-term GnRHa therapy.
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